Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail of cancer drugs tested for tough leukemia

NCT ID NCT01861314

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This early-phase trial tests a combination of three drugs — bortezomib, sorafenib, and decitabine — in patients with acute myeloid leukemia (AML), especially those who are older or have hard-to-treat forms. The main goal is to find the safest dose and see how well patients tolerate the combination. Researchers will also look for early signs that the drugs are working against the leukemia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bortezomib, sorafenib tosylate, and decitabine
What this could lead to
If this works, it could point toward a new treatment option for older or hard-to-treat AML patients who cannot have standard chemotherapy.
What could go wrong
This is a very early phase 1 trial with only 15 participants, focused on safety and dosing — not yet testing if the combination truly works. Side effects from the three drugs may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia therapy related acute myeloid leukemia and myelodysplastic syndrome therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY RECURRENT ADULT ACUTE MYELOID LEUKEMIA SECONDARY ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.